Welcome to our dedicated page for Delcath Sys SEC filings (Ticker: DCTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Delcath Systems, Inc. filings document an interventional oncology company with Nasdaq-listed common stock and a liver-directed drug-device platform. Form 8-K reports furnish quarterly and annual financial results, preliminary results, Regulation FD presentations, product revenue for HEPZATO KIT and CHEMOSAT, clinical publication updates for CHOPIN, and board-authorized share repurchase activity.
The company’s proxy materials cover annual meeting governance, executive compensation, equity awards, and related shareholder voting disclosures. Delcath filings also identify its common stock, par value, trading symbol DCTH, and Nasdaq Capital Market listing, while formal exhibits provide press releases and corporate presentations used for operating, clinical, and capital-structure disclosures.
Delcath Systems chief medical officer Vojo Vukovic received new equity awards. On February 17, 2026, he was granted stock options for 56,500 shares at an exercise price of $0.00 per share and 28,250 restricted stock units (RSUs).
The options vest at a rate of one‑thirty‑sixth per month starting on February 17, 2026, as long as he remains an employee under the company’s 2020 Omnibus Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock, with one‑third vesting on February 17, 2027 and the remaining two‑thirds in equal annual installments over the following two years, subject to continued service.
Rook Martha S. reported acquisition or exercise transactions in this Form 4 filing.
Delcath Systems chief operating officer Martha S. Rook reported new equity compensation grants. She received stock options for 56,500 shares at no cost, vesting at a rate of one‑thirty‑sixth per month starting on February 17, 2026, as long as she remains an employee.
Rook also received 28,250 restricted stock units, each representing one share of common stock. One‑third of these RSUs will vest on February 17, 2027, with the remaining two‑thirds vesting in equal annual installments over the following two years, subject to her continuous service.
Delcath Systems, Inc. reported that Chief Executive Officer Michel Gerard J acquired equity awards consisting of stock options and restricted stock units. He received stock options for 195,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
The option vests at a rate of one‑thirty‑sixth per month starting on February 17, 2026, continuing monthly while he remains an employee under the company’s 2020 Omnibus Equity Incentive Plan. He was also granted 97,500 restricted stock units, each representing a contingent right to one share of common stock.
One‑third of the RSUs vest on February 17, 2027, with the remaining two‑thirds vesting in equal annual installments over the following two years, subject to his continuous service through each vesting date.
Delcath Systems, Inc. received an amended Schedule 13D/A from the Rosalind group detailing their equity stake and governance role. Rosalind Advisors, Inc. reports beneficial ownership of 6,719,993 shares of common stock equivalents, representing 9.9% of the class after applying ownership blockers. These securities are primarily preferred stock and warrants that cannot be converted or exercised if ownership would exceed 9.99% for preferred shares or 4.99% for warrants. The percentages are based on 35,313,718 common shares outstanding as of October 27, 2025. Rosalind Master Fund L.P. reports 2,871,335 shares (4.4%), and Rosalind Opportunities Fund I L.P. reports 3,530,215 shares (4.9%). Steven Salamon and Gil Aharon, Canadian citizens and portfolio managers at Rosalind Advisors, also report 9.9% beneficial ownership each and serve as independent directors of Delcath, with board terms scheduled to run through the 2024 and 2025 annual meetings, respectively.
Delcath Systems, Inc. furnished an update with preliminary, unaudited financial and operating results for the fourth quarter and full year ended December 31, 2025. The company disclosed that as of December 31, 2025 it had 25 active sites utilizing its HEPZATO KIT treatment and approximately 34.7 million shares of common stock issued and outstanding. Delcath also reported that it achieved positive operating cash for the quarter ended December 31, 2025, signaling an important shift in quarterly cash generation. All figures are preliminary, subject to completion of the financial close process and potential audit adjustments. The details are provided in a press release and corporate presentation furnished as exhibits.
Delcath Systems, Inc. director reports open-market stock purchase. A company director bought 4,386 shares of Delcath Systems common stock on 11/21/2025 at a price of $8.89 per share in a transaction reported as a purchase. After this trade, the director beneficially owns 14,936 shares, held directly. The filing is a routine Form 4 disclosure showing insider ownership and the latest change in the director's personal investment in Delcath stock.
Delcath Systems, Inc. announced that its board of directors has authorized a share repurchase program. Under this program, the company may buy back up to $25 million of its outstanding common stock. Repurchases may occur from time to time and are subject to market conditions, giving the company flexibility in how and when it executes the program.
Delcath Systems (DCTH) reported an insider share purchase by its Chief Executive Officer and Director, Gerard Michel. On 11/11/2025, he purchased 11,500 shares of common stock at $8.526 per share, coded as “P,” indicating a purchase. Following this transaction, his beneficial ownership stands at 330,834 shares, held directly.
Delcath Systems (DCTH) reported strong Q3 2025 growth as product revenue reached $20.6 million, up from $11.2 million a year ago. HEPZATO KIT drove results with $19.3 million, while CHEMOSAT contributed $1.3 million. Gross profit was $17.9 million.
The quarter showed a small operating loss of $0.4 million but net income of $0.8 million, aided by $0.8 million of net interest income. For the first nine months, revenue rose to $64.5 million (from $22.1 million), with operating income of $2.8 million and net income of $4.6 million, marking a turnaround from last year’s loss.
Cash and cash equivalents were $41.8 million and short‑term investments were $47.1 million at September 30, 2025. Operating cash flow was $14.3 million year‑to‑date, supported by warrant and option exercises in financing activities. The company reiterated it believes existing cash, investments, and operating cash flow are sufficient for at least 12 months. As of October 27, 2025, 35,313,718 common shares were outstanding.
Clinical updates included positive Phase 2 CHOPIN data combining CHEMOSAT with checkpoint inhibitors, and ongoing Phase 2 programs in liver‑dominant colorectal and breast cancers.
Delcath Systems (DCTH) filed an 8-K to furnish a press release announcing financial results and business highlights for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 under Item 2.02. The company states the information, including the press release, is furnished, not filed under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K was signed by CFO Sandra Pennell.